Clinical Trials
Advancing Urology Through Research
We’re keeping Southeast Michigan at the forefront of urology care, and giving patients access to promising treatments and diagnostics, with our robust clinical research.
Each clinical trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 248-786-0467.
Explore These Clinical Trials at Michigan Institute of Urology
Clinical research trials play an essential role in bringing new treatments and diagnostics to our patients. By participating you’ll gain the reassurance and security of being closely monitored, and the satisfaction of knowing that you’re playing an important role in advancing medicine.
These clinical trials are currently available at Michigan Institute of Urology.
Arastep 21492 - NO LONGER ENROLLING PATIENTS
Bayer HealthCare Pharmaceuticals Inc.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-Risk Biochemical Recurrence (BCR) or Prostate Cancer
Butterfly CL-BM14-001
Butterfly Medical Ltd.
A prospective, randomized, controlled, blinded study to assess the Safety and Efficacy of the Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients.
Ironwood C3300‑201 - NO LONGER ENROLLING PATIENTS
Ironwood Pharmaceuticals, Inc.
A Phase 2 Study of IW‑3300 for the Treatment of Bladder Pain in Subjects with Interstitial Cystitis/Bladder Pain Syndrome.
Keynote MK-3475-676
Merck
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676)
Libertas 56021927PCR3020
Janssen Research and Development, LLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Patapsco D419JC00002
AstraZeneca Pharmaceutical LP
A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination with Durvalumab in Adult BCG-naïve, High-risk Non–Muscle-Invasive Bladder Cancer Participants.
Primordium 56021927PCR3015 - NO LONGER ENROLLING PATIENTS
Janssen Research and Development, LLC
A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort
Sunrise-1 JNJ- 17000139BLC2001
Janssen Research and Development, LLC
A Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Sunrise-4 JNJ-17000139BLC2002
Janssen Research and Development, LLC
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Vapor-2 4760-001
Francis Medical, Inc
Prospective, Multicenter, Single-Arm Study of Vanquish™ Water Vapor Ablation for Prostate Cancer
